Issue Date: January 15, 2007
BioVectra scores production contract
BioVectra, a Canadian custom pharmaceutical manufacturer, has won the contract to supply Helix BioPharma with bulk quantities of L-DOS47, consisting of a single-domain antibody linked to the enzyme urease. BioVectra will make clinical-trial quantities of the drug, for which Helix is currently completing preclinical tests as a lung cancer treatment. According to Helix, BioVectra was selected because it has biopharmaceutical production capabilities and is a major supplier of urease.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society